Status:
COMPLETED
Teneligliptin and Atorvastatin DDI Study
Lead Sponsor:
Handok Inc.
Conditions:
Diabete Mellitus
Eligibility:
MALE
19-45 years
Phase:
PHASE1
Brief Summary
A randomized, open-label, cross-over, multiple dosing study to evaluate drug-drug interaction between Teneligliptin and Atorvastatin in healthy male adults
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Healthy male adult 19 to 45 years
- Body weight ≥ 50kg, and BMI between 18-29kg/m2 at screening
- Subject who agrees to use a medically acceptable double-barrier method of contraception and not to donate sperms from the first dose until 2 months after the last dose.
- Subject who was given, and fully understood, the information about the study, and has provided voluntary written informed consent to participate in the study and agreed to comply with the study requirements.
Exclusion
Key Trial Info
Start Date :
January 11 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 25 2019
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03769870
Start Date
January 11 2019
End Date
February 25 2019
Last Update
May 30 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Korea Universitiy Guro Hospital
Seoul, South Korea